HomeCompareRTNB vs PFE

RTNB vs PFE: Dividend Comparison 2026

RTNB yields 2000000.00% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RTNB wins by $1.6247481716182984e+23M in total portfolio value
10 years
RTNB
RTNB
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.6247481716182984e+23M
Annual income
$147,608,011,402,949,780,000,000,000,000.00
Full RTNB calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — RTNB vs PFE

📍 RTNB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRTNBPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RTNB + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RTNB pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RTNB
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$125,466,809,692,507,310,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, RTNB beats the other by $125,466,809,692,507,310,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RTNB + PFE for your $10,000?

RTNB: 50%PFE: 50%
100% PFE50/50100% RTNB
Portfolio after 10yr
$8.123740858091492e+22M
Annual income
$73,804,005,701,474,890,000,000,000,000.00/yr
Blended yield
90.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

RTNB
No analyst data
Altman Z
-10.1
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RTNB buys
0
PFE buys
0
No recent congressional trades found for RTNB or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRTNBPFE
Forward yield2000000.00%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$1.6247481716182984e+23M$51.1K
Annual income after 10y$147,608,011,402,949,780,000,000,000,000.00$27,210.54
Total dividends collected$1.6146053563276882e+23M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RTNB vs PFE ($10,000, DRIP)

YearRTNB PortfolioRTNB Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$100,010,700$100,000,000.00$9,161$701.38+$100.00MRTNB
2$467,446,731,075$467,339,719,626.17$8,610$859.79+$467446.72MRTNB
3$1,021,215,363,816,662$1,020,715,195,814,411.90$8,366$1,081.25+$1021215363.81MRTNB
4$1,043,112,617,104,109,200$1,042,019,916,664,825,300.00$8,483$1,405.66+$1043112617104.10MRTNB
5$498,482,143,759,731,400,000$497,366,013,259,430,040,000.00$9,084$1,907.24+$498482143759731.38MRTNB
6$111,599,275,650,097,780,000,000$111,065,899,756,274,860,000,000.00$10,418$2,732.78+$111599275650097776.00MRTNB
7$11,738,678,336,351,557,000,000,000$11,619,267,111,405,953,000,000,000.00$13,007$4,193.56+$11738678336351557632.00MRTNB
8$583,674,362,697,175,100,000,000,000$571,113,976,877,278,900,000,000,000.00$18,010$7,005.87+$583674362697175072768.00MRTNB
9$13,894,210,989,607,547,000,000,000,000$13,269,679,421,521,570,000,000,000,000.00$28,216$12,979.89+$1.3894210989607547e+22MRTNB
10$162,474,817,161,829,840,000,000,000,000$147,608,011,402,949,780,000,000,000,000.00$51,081$27,210.54+$1.6247481716182984e+23MRTNB

RTNB vs PFE: Complete Analysis 2026

RTNBStock

root9B Holdings, Inc. provides cybersecurity and business advisory services primarily in regulatory risk mitigation in the United States and internationally. The company's Cyber Solutions segment offers cyber security, advanced technology training, operational support, and consulting services. This segment provides cyber operations assessments, analysis and testing, cyber training, forensics, exploitation, and strategic defense planning services. Its Business Advisory Solutions segment offers anti-money laundering (AML) operational, investigative, and remediation services, as well as AML risk advisory and consulting services in the areas of risk, data, organizational change, and cyber. This segment also conducts high-end investigations with expertise in services ranging from complex financial crime and intellectual property issues to conduct anti-bribery investigations or due diligence on a potential partner or customer. root9B Holdings, Inc. serves Fortune 500 companies, medium-sized businesses, and governmental entities. The company was formerly known as root9B Technologies, Inc. and changed its name to root9B Holdings, Inc. in December 2016. root9B Holdings, Inc. was founded in 1995 and is based in Phoenix, Arizona.

Full RTNB Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this RTNB vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RTNB vs SCHDRTNB vs JEPIRTNB vs ORTNB vs KORTNB vs MAINRTNB vs JNJRTNB vs MRKRTNB vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.